Fig. 1

JMJD6 expression is upregulated and associated with poor prognosis in Lung cancer patients. (A) TIMER 2.0 database was used for pan-cancer analysis of JMJD6. (B) The relative expression levels of JMJD6 in lung cancer tissues and adjacent normal tissues in TCGA database. (C) Accuracy of assignment with paired tumor and normal samples from TCGA lung cancer cohort. (D, E) CPTAC data analysis showed that the expression level of JMJD6 in lung cancer tissues was significantly higher than that in normal tissues (D). Moreover, elevated JMJD6 expression level was significantly correlated with higher tumor grade of lung cancer (E). (F) Kaplan-Meier analysis of the TCGA dataset showed that high JMJD6 expression predicted poor overall survival. log-rank test, P = 0.0021. (G) The Kaplan-Meier survival analysis was used to analyze the prognosis of JMJD6 in lung cancer from TCGA and GEO database. P values were determined by log-rank test (P = 1.2e-05). (H, I, J) Kaplan-Meier survival analysis of stage I, II and III lung cancer patients using TCGA database. (K) The expression of JMJD6 in paired normal lung tissues and lung cancer tissues was analyzed by immunohistochemistry, and the quantitative results of immunohistochemical scores are on the right. (L) RT-qPCR was used to analyze the expression levels of JMJD6 in four different lung cancer cell lines and normal lung epithelial cell BEAS-2B, and statistical analysis was performed. (M) Cell annotated t-SNE plot, with different coloured dots representing the different cell type information annotated. (N) Tumour cell clustering t-SNE plot, 0–4 represent 5 different cell clusters, respectively. (O) Heatmap showing expression of significantly upregulated top5 marker genes in 5 different clusters of tumour cells. (P) Violin plots showing JMJD6 gene expression in various tumour cell subpopulations. Data are expressed as mean ± SD.*p < 0.05; **p < 0.01; ***p < 0.001